154 related articles for article (PubMed ID: 27208881)
1. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Navrátil M; Tykvart J; Schimer J; Pachl P; Navrátil V; Rokob TA; Hlouchová K; Rulíšek L; Konvalinka J
FEBS J; 2016 Jul; 283(13):2528-45. PubMed ID: 27208881
[TBL] [Abstract][Full Text] [Related]
2. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Hlouchova K; Barinka C; Konvalinka J; Lubkowski J
FEBS J; 2009 Aug; 276(16):4448-62. PubMed ID: 19678840
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of human glutamate carboxypeptidase III.
Hlouchová K; Barinka C; Klusák V; Sácha P; Mlcochová P; Majer P; Rulísek L; Konvalinka J
J Neurochem; 2007 May; 101(3):682-96. PubMed ID: 17241121
[TBL] [Abstract][Full Text] [Related]
4. GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
Vorlova B; Knedlik T; Tykvart J; Konvalinka J
Front Biosci (Landmark Ed); 2019 Mar; 24(4):648-687. PubMed ID: 30844704
[TBL] [Abstract][Full Text] [Related]
5. Deletion of glutamate carboxypeptidase II (GCPII), but not GCPIII, provided long-term benefits in mice with traumatic brain injury.
Ji T; Pang Y; Cheng M; Wang R; Chen X; Zhang C; Liu M; Zhang J; Zhong C
CNS Neurosci Ther; 2023 Dec; 29(12):3786-3801. PubMed ID: 37349952
[TBL] [Abstract][Full Text] [Related]
6. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
8. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
9. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Mlcochová P; Plechanovová A; Barinka C; Mahadevan D; Saldanha JW; Rulísek L; Konvalinka J
FEBS J; 2007 Sep; 274(18):4731-41. PubMed ID: 17714508
[TBL] [Abstract][Full Text] [Related]
10. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Klusák V; Barinka C; Plechanovová A; Mlcochová P; Konvalinka J; Rulísek L; Lubkowski J
Biochemistry; 2009 May; 48(19):4126-38. PubMed ID: 19301871
[TBL] [Abstract][Full Text] [Related]
11. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.
Pavlícek J; Ptácek J; Barinka C
Curr Med Chem; 2012; 19(9):1300-9. PubMed ID: 22304708
[TBL] [Abstract][Full Text] [Related]
12. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
13. Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.
Navrátil M; Ptáček J; Šácha P; Starková J; Lubkowski J; Bařinka C; Konvalinka J
FEBS J; 2014 Jul; 281(14):3228-42. PubMed ID: 24863754
[TBL] [Abstract][Full Text] [Related]
14. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.
Barinka C; Mlcochová P; Sácha P; Hilgert I; Majer P; Slusher BS; Horejsí V; Konvalinka J
Eur J Biochem; 2004 Jul; 271(13):2782-90. PubMed ID: 15206943
[TBL] [Abstract][Full Text] [Related]
15. The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
Bzdega T; Crowe SL; Ramadan ER; Sciarretta KH; Olszewski RT; Ojeifo OA; Rafalski VA; Wroblewska B; Neale JH
J Neurochem; 2004 May; 89(3):627-35. PubMed ID: 15086519
[TBL] [Abstract][Full Text] [Related]
16. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.
Tykvart J; Schimer J; Jančařík A; Bařinková J; Navrátil V; Starková J; Šrámková K; Konvalinka J; Majer P; Šácha P
J Med Chem; 2015 May; 58(10):4357-63. PubMed ID: 25923815
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.
Davis MI; Bennett MJ; Thomas LM; Bjorkman PJ
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):5981-6. PubMed ID: 15837926
[TBL] [Abstract][Full Text] [Related]
18. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.
Lucaroni L; Georgiev T; Prodi E; Puglioli S; Pellegrino C; Favalli N; Prati L; Manz MG; Cazzamalli S; Neri D; Oehler S; Bassi G
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):957-961. PubMed ID: 36184692
[TBL] [Abstract][Full Text] [Related]
20. A high-resolution structure of ligand-free human glutamate carboxypeptidase II.
Barinka C; Starkova J; Konvalinka J; Lubkowski J
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Mar; 63(Pt 3):150-3. PubMed ID: 17329803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
